An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Tempus Announces Prospective Study for Biomarker Discovery in Small Cell Lung Cancer
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Tempus has announced a prospective study named Sculptor in collaboration with AstraZeneca (AZN) to identify biomarkers for small cell lung cancer (SCLC). The study, currently open for enrollment, aims to enhance therapeutic targeting for this aggressive cancer, which affects around 13% of lung cancer patients in the U.S. The initiative leverages Tempus' molecular profiling capabilities and aims to expand its dataset nationally through the TIME Trial Network, enhancing precision medicine approaches for SCLC treatment.
Positive
Collaboration with AstraZeneca for the Sculptor study, enhancing research on SCLC.
Aims to identify biomarkers to improve therapeutic options for small cell lung cancer patients.
Study open for enrollment, indicating progress in research and patient involvement.
Utilizes Tempus' extensive molecular profiling portfolio to gather essential insights.
Negative
None.
CHICAGO--(BUSINESS WIRE)--
Tempus, a leader in artificial intelligence and precision medicine, today announced a prospective study (NCT05257551), in collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), that aims to identify biomarkers of response in patients with small cell lung cancer (SCLC). The study, titled Sculptor, is co-sponsored by Tempus and AstraZeneca’s Personalize SCLC Initiative and is currently open for enrollment.
In the United States, lung cancer is the second most common cancer, and approximately 13% of people diagnosed with lung cancer have SCLC, according to the American Cancer Society. SCLC is an aggressive disease characterized by rapid growth, early metastasis, and acquired therapeutic resistance in which there is a high unmet need for therapeutic targets. To date, there are limited ways to stratify this specific patient population and limited defined therapeutic targets or associated treatments.
The Sculptor study is leveraging Tempus’ comprehensive portfolio of molecular profiling offerings to gather the insights necessary to support this kind of early research, with the goal of identifying distinct segments that may benefit from emerging therapies, or a treatable target from which to develop an associated therapy to treat patients with SCLC. This study is currently active at five TIME Trial Network sites, with plans to expand to additional providers across the country to ensure the study’s dataset is representative of the overall SCLC patient population in the United States.
“This collaborative study will facilitate the investigation of SCLC patient populations to provide us with key insights in hopes of enabling pharmaceutical solutions that increase the overall survival of this disease,” said Kate Sasser, PhD, Chief Scientific Officer at Tempus. “This type of early-stage, prospective study is only possible when combining Tempus’ comprehensive sequencing capabilities, multimodal database, and just-in-time clinical trial network.”
“We are excited to announce commencement of the first clinical trial stemming from our strategic collaboration with Tempus,” said Cristian Massacesi, Chief Medical Officer & Oncology Chief Development Officer, AstraZeneca. “AstraZeneca’s investigation of novel therapies for SCLC sub-populations is another example of our precision medicine approach and mission to put patients first and follow the science.”
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make near real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
What is the Sculptor study involving AstraZeneca (AZN)?
The Sculptor study is a collaborative research initiative between Tempus and AstraZeneca aimed at identifying biomarkers in patients with small cell lung cancer (SCLC).
When did Tempus announce its collaboration with AstraZeneca (AZN)?
Tempus announced the collaboration and the commencement of the Sculptor study on January 5, 2023.
What is the goal of the Sculptor study related to small cell lung cancer (SCLC)?
The goal of the Sculptor study is to identify biomarkers that could lead to improved therapeutic targeting and treatment options for patients with SCLC.
Where is the Sculptor study currently active?
The Sculptor study is currently active at five TIME Trial Network sites in the U.S., with plans for national expansion.
What percentage of lung cancer patients have small cell lung cancer (SCLC)?
Approximately 13% of lung cancer patients in the U.S. are diagnosed with small cell lung cancer (SCLC).
